Flagship Pioneering — 2022 Investments

4 investments dated 2022 · listed companies and verified rows first · show all

Vesalius Therapeuticsvesaliustx.comSeries A · Mar 2022 · $75M✓ verified

Vesalius Therapeutics develops a computational platform that identifies distinct disease subtypes within common diseases like heart failure, diabetes, and Alzheimer's by analyzing patient data and gene circuits, then uses proprietary cell-based models to discover targeted drug candidates.

AI & Machine LearningBiotechDeep TechCambridge, US

Yasir Al-Wakeel(CEO)in

Co-investorsARCH Venture Partners Sofinnova Ventures

Senda Biosciencessendabiosciences.comSeries C · Aug 2022 · $120M

Co-investorsBoutique Venture Partners Stage 1 Ventures

Syros Pharmaceuticals, Inc.syros.comSep 2022

Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.

BiotechCambridge, US

Nancy Simonian(CEO)Peter Wirth(Director)Mark Alles(Director)Philip Sharp(Director)Richard A. Young(Director)Sue Gail Eckhardt(Director)

Co-investorsAisling Capital ARCH Venture Partners Quan Capital Alexandria Ally Bridge Group Bain Capital +11 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Zoī

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.